Prefrontal Oscillations in Social Anxiety Disorder (POSAD)
Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 25, 2019
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Prefrontal Oscillations in Social Anxiety Disorder" (POSAD) is investigating a specific brain activity pattern in people with social anxiety disorder. Researchers believe that slow electrical waves in a part of the brain called the prefrontal cortex might help identify those with severe anxiety. By studying these brain patterns in humans, the trial aims to better understand how anxiety works and potentially improve treatment options in the future.
To participate in this study, individuals must have been diagnosed with social anxiety disorder and be registered with the French national health insurance system. Participants should also be able to understand the study details and provide their consent to join. However, certain health conditions or recent changes in medication may disqualify someone from participating. If selected, participants can expect to undergo tests that will measure their brain activity while researchers gather information to better understand anxiety. It's an exciting opportunity to contribute to important research in mental health!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Social anxiety disorder as defined in DSM-5
- • Full understanding of the protocol
- • Obtaining informed consent from study subjects before or at inclusion at the latest
- • Being registered in the french national health insurance service (Sécurité Sociale) (or equivalent)
- Exclusion Criteria:
- • Active medical co-morbidity including severe hypertension, cardiac insufficiency, Raynaud syndrome, diabetes mellitus, renal insufficiency, adrenal insufficiency, Cushing syndrome and epilepsy
- • Severe neurological co-morbidity, including but not limited to Parkinson's disease and multiple sclerosis
- • Long-term corticotherapy
- • History of significant head injury, defined by loss of consciousness
- • Being diagnosed with another major psychiatric condition (DSM5) including bipolar disorder and schizophrenia or substance/alcohol use disorder; with the exception of major depressive disorder and nicotine use disorder
- • Suicidal risk evaluated as moderate to high in the MINI questionnaire
- * initiation of a psychotropic treatment or change in the dose of ongoing psychotropic treatment within 3 days prior to each visit and including:
- • 1. antidepressant treatments with selective serotonin recapture inhibitors, serotonin and norepinephrine inhibitors, alpha2-presynaptic adrenoreceptors (mirtazapine, mianserin), tricyclic
- • 2. anxiolytic drugs including benzodiazepines and anti-histamine
- • 3. antipsychotic drugs
- • Acute alcohol intake 2 days prior to each visit (inclusion, experimental sessions)
- • Pregnancy or breastfeeding.
- • Ongoing hospitalization without consent (decision of a third-party: medical, justice)
About Institut National De La Santé Et De La Recherche Médicale, France
The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Patients applied
Trial Officials
Olivier Doumy, MD
Principal Investigator
Centre Hospitalier Charles Perrens, Bordeaux; INRA NutriNeuro, Bordeaux; Université de Bordeaux, France
Alexandra Bouvard, MD
Principal Investigator
Centre Hospitalier Charles Perrens, Bordeaux; Université de Bordeaux, France
Cyril Herry, PhD
Study Director
Neurocentre Magendie, Inserm U1215, Bordeaux, France
Cyril Dejean, PhD
Principal Investigator
Neurocentre Magendie, Inserm U1215, Bordeaux, France
Thomas Bienvenu, PhD
Principal Investigator
Centre Hospitalier Charles Perrens, Bordeaux; Neurocentre Magendie, Inserm U1215, Bordeaux, France
Jacques Taillard, MS
Principal Investigator
GENPHASS, CHU de Bordeaux
Bruno Aouizerate, MD-PhD
Study Chair
Centre Hospitalier Charles Perrens, Bordeaux; INRA NutriNeuro, Bordeaux; Université de Bordeaux, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials